Global Finished Dosage Manufacturing Landscape 2026

Finished dosage listings are concentrated in a few forms. Tablets alone account for 67,172 listings — 50.5% of the total and more than three times the next form — and Tablets, Injectables & Parenterals and Capsules together hold 77.5%. Tablets also have the deepest portfolios: 27.3 listings per company against 9.8 for injectables and 10.4 for capsules, so the tablet figure is driven by companies that publish large product ranges rather than by many companies publishing a few products each. Below the top three, the forms thin out quickly: seven of the fourteen have fewer than 3,000 listings each.

Finished dosage manufacturers are concentrated in a small number of countries. The top five — India, China, Viet Nam, Republic of Korea and the United States — hold 54.7% of the 5,379 manufacturers that have a country recorded, the top ten hold 72.2%, and the top twenty 84.8%. India leads with 790 (14.7%), followed by China with 683 and Viet Nam with 558.

The ranking is not equally firm across countries. When researcher-affiliation and job-posting records are removed, the order of the top five does not change, but the gaps do: Viet Nam keeps 91% of its count (558 to 509), India 79%, China 75% and Republic of Korea 72%, so China and Viet Nam end up almost level (511 against 509). The United States keeps only 45%, falling from 420 to 189 — more than half of its listed finished dosage manufacturers come from researcher-affiliation records. These records are created from the employer named on a researcher’s public profile. In a small random sample they were mostly pharmaceutical companies — often the local subsidiaries of multinational groups — with a minority of academic institutions. An employer listing alone does not show that the entity manufactures finished dosage forms, which is why this view treats them as the least manufacturing-specific source. The honest reading is a range, not a point: the United States holds between roughly 190 and 420 finished dosage manufacturers in this database depending on which sources are counted.

India has the most manufacturers declaring Tablets (321, ahead of Viet Nam’s 280) and Injectables & Parenterals (178, ahead of Republic of Korea’s 126). Viet Nam has the most declaring Capsules (314), Syrups (218), Powders (211) and Creams, Lotions & Ointments (129), and also leads in Suspensions (77), Drops (54), Sprays (47) and Suppositories (17). Republic of Korea is second in injectables (126) and leads Transdermal Patches (11 against 8 for Viet Nam).

China is the outlier. It has 683 finished dosage manufacturers but only 20 declare Tablets, 38 Capsules and 96 Injectables. Adding every form-level count for China gives at most 181, so at least 502 of China’s 683 manufacturers (73%) record Finished Dosage Forms without naming a dosage form. The same limit applies elsewhere. Form-level comparisons in this section are therefore comparisons between manufacturers who specified a form, not a complete picture of any country’s product mix.

Across the whole database, 2,780 of the 5,415 finished dosage manufacturers (51.3%) declare at least one specific dosage form; the other 2,635 (48.7%) record the Finished Dosage Forms category only.

Most manufacturers that name a form name only one: 58.1% declare a single dosage form, and 41.9% declare two or more. Tablets sit in five of the eight most common pairs, and 644 manufacturers — 23.2% of those declaring a form — declare both tablets and capsules, the largest overlap in the database. Only 104 declare six or more forms. These are patterns in how profiles are filled in; they do not show what any plant is equipped to produce.

Finished dosage listings are concentrated in three forms. Tablets hold 67,172 of 132,903 listings (50.5%); with Injectables & Parenterals and Capsules the share is 77.5%. Tablets also have the deepest product ranges at 27.3 listings per company. Seven of the fourteen forms hold fewer than 3,000 listings each.

The top five countries hold 54.7% of finished dosage manufacturers that have a country recorded, and the top ten hold 72.2%. India leads with 790, ahead of China (683) and Viet Nam (558). The order of the top five is stable under the source-sensitivity check, but the size of the United States figure is not: 420 with all records, 189 without researcher-affiliation and job-posting records.

Dosage-form declarations vary by country. India leads in tablets and injectables, Viet Nam in capsules, syrups, powders and creams, and Republic of Korea is the second-largest in injectables and the largest in transdermal patches. These contrasts exist only among manufacturers that named a form; almost half of all finished dosage manufacturers (48.7%), and at least 73% of China’s, did not.

58.1% of the manufacturers that declare a form declare one. The tablets-and-capsules pairing is the most common combination (644). Few manufacturers (104) declare six or more forms.

About half of the finished dosage manufacturer records come from national drug-registry data, a quarter from trade directories, 16.9% from researcher-affiliation records and 5.8% from job-posting data. The mix explains much of what the rankings show, and it should be read alongside every country figure in this report.

Start from the dosage form, not the country. A search for a specific form — tablets, injectables, capsules — returns the companies that published listings in it; the country figures above show where those companies are concentrated in the database. Treat the declared manufacturer counts as a starting list and check the manufacturer’s own documentation before relying on a capability, since the platform does not verify licences or capacity.

Profile completeness changes how a company appears in this analysis. Manufacturers that name their dosage forms are the only ones that can be matched to a form-level search; 48.7% have not. A complete profile — roles, dosage forms, country and listings — is what turns a record into something a buyer can find.

• Browse all finished dosage listings: Finished Dosage Forms
• By dosage form: Tablets · Capsules · Injectables & Parenterals · Powders · Syrups · Creams, Lotions & Ointments · Drops · Suspensions
• By country of manufacture recorded on the listing (made in): India · China · Viet Nam · Republic of Korea · United States · Japan · Germany · France · Italy · Spain

The country pages above filter on the made-in country recorded on each listing, a separate field from the company’s registered country used in the tables of this report, so the two can differ.

All figures are derived from the PharmaCountry platform database. No external market data, third-party dataset or published industry estimate is used. Figures were produced by aggregation queries run on the production database on 5 October 2026, so every table and chart describes the same snapshot.

Company and listing records enter PharmaCountry through several routes: profiles created by companies themselves, and records indexed from public sources such as national drug registries, trade directories, professional-profile data and job postings. The database records which source each company record originates from; Table 5 reports that breakdown for the finished dosage manufacturers. It is not a regulatory register, a customs dataset or a census of the industry.

Only records with active status are counted. The denominator for all company percentages is 33,356 active companies. Listing counts are active-only.

A finished dosage manufacturer is a distinct active company record carrying the Manufacturer role and the Finished Dosage Forms first-level category on the same profile line; each company is counted once. A dosage form is declared when a profile line with the Manufacturer role names the form as a second-level category. Classifications are entered on profiles and are not independently verified.

Listings are product listings (trade type sell). A listing filed under more than one dosage form is counted in each row, so the rows of Table 1 are compared with each other rather than summed; the distinct total (132,903) is used for percentages. Listings inherit the country of the publishing company.

Country is the registered country on the company record. It is not necessarily where manufacturing takes place. 36 finished dosage manufacturers have no country and are excluded from country shares.

Table 2’s second view removes finished dosage manufacturers whose record originates from researcher-affiliation data (917) or job-posting data (315), because those sources describe where individuals work rather than where medicines are manufactured. The remaining 4,183 still include registry and trade-directory records, which carry their own coverage patterns. The view shows how sensitive the ranking is; it is not a corrected ranking.

The platform has no automated de-duplication. A company registered more than once is counted more than once, and an unknown number of duplicates remains.

Database snapshot: 5 October 2026.

PharmaCountry’s database represents companies and listings indexed on the platform and should not be interpreted as a complete census of the global pharmaceutical industry.

• Source mix. The database combines registry, directory, researcher-affiliation, job-posting and company-created records. Country and dosage-form counts reflect that mix.
• Unspecified dosage forms. 48.7% of finished dosage manufacturers (2,635) name no dosage form, and at least 2.2% of FDF listings are not filed under a form.
• Self-declared classification. Roles, categories and countries are not independently verified.
• Capability is not capacity. A declared dosage form does not show output, capacity, licensing or quality status.
• Listings differ from manufacturers. Companies listing a form include non-manufacturers; only 40.8% of finished dosage manufacturers publish any listing.

Source: PharmaCountry database, 5 October 2026. The figures represent companies and listings indexed in the PharmaCountry platform and should not be interpreted as a complete census of the global pharmaceutical industry.

Last updated: 5 October 2026.